Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

Carbon nanohorn modified platinum electrodes for improved immobilisation of enzyme in the design of glutamate biosensors.

Ford R, Devereux SJ, Quinn SJ, O'Neill RD.

Analyst. 2019 Aug 2. doi: 10.1039/c9an01085h. [Epub ahead of print]

PMID:
31373591
2.

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.

Hillmen P, Rawstron AC, Brock K, Muñoz-Vicente S, Yates FJ, Bishop R, Boucher R, MacDonald D, Fegan C, McCaig A, Schuh A, Pettitt A, Gribben JG, Patten PEM, Devereux S, Bloor A, Fox CP, Forconi F, Munir T.

J Clin Oncol. 2019 Jul 11:JCO1900894. doi: 10.1200/JCO.19.00894. [Epub ahead of print]

PMID:
31295041
3.

Seasonal Food Insecurity among Farm Workers in the Northern Cape, South Africa.

Devereux S, Tavener-Smith L.

Nutrients. 2019 Jul 5;11(7). pii: E1535. doi: 10.3390/nu11071535.

4.

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.

Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM.

Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761.

5.

Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial.

Phillips EH, Devereux S, Radford J, Mir N, Adedayo T, Clifton-Hadley L, Johnson R.

Leuk Lymphoma. 2019 Feb 18:1-4. doi: 10.1080/10428194.2019.1576870. [Epub ahead of print] No abstract available.

PMID:
30773077
6.

Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.

O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA.

Am J Hematol. 2019 May;94(5):554-562. doi: 10.1002/ajh.25436. Epub 2019 Mar 8.

7.

Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Barrientos JC, O'Brien S, Brown JR, Kay NE, Reddy NM, Coutre S, Tam C, Mulligan S, Jaeger U, Devereux S, Pocock C, Robak T, Schuster SJ, Schuh A, Gill D, Bloor A, Dearden C, Moreno C, Cull G, Hamblin M, Jones JA, Eckert K, Solman IG, Suzuki S, Hsu E, James DF, Byrd JC, Hillmen P.

Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):803-813.e7. doi: 10.1016/j.clml.2018.08.007. Epub 2018 Aug 18.

8.

Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.

Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre SE, Quach H, Gaidano G, Maslyak Z, Stevens DA, Moreno C, Gill DS, Flinn IW, Gribben JG, Mokatrin A, Cheng M, Styles L, James DF, Kipps TJ, Ghia P.

Am J Hematol. 2018 Nov;93(11):1402-1410. doi: 10.1002/ajh.25259. Epub 2018 Oct 9.

9.

Multimodal Microscopy Distinguishes Extracellular Aggregation and Cellular Uptake of Single-Walled Carbon Nanohorns.

Devereux SJ, Cheung S, Daly HC, O'Shea DF, Quinn SJ.

Chemistry. 2018 Sep 20;24(53):14162-14170. doi: 10.1002/chem.201801532. Epub 2018 Aug 22.

PMID:
30028043
10.

Calcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cells.

Mele S, Devereux S, Pepper AG, Infante E, Ridley AJ.

Blood Adv. 2018 Jul 10;2(13):1551-1561. doi: 10.1182/bloodadvances.2017014506.

11.

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.

Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P.

Haematologica. 2018 Sep;103(9):1502-1510. doi: 10.3324/haematol.2018.192328. Epub 2018 Jun 7.

12.

In vitro and in vivo evidence for uncoupling of B-cell receptor internalization and signaling in chronic lymphocytic leukemia.

Coulter EM, Pepper A, Mele S, Folarin N, Townsend W, Cuthill K, Phillips EH, Patten PEM, Devereux S.

Haematologica. 2018 Mar;103(3):497-505. doi: 10.3324/haematol.2017.176164. Epub 2017 Dec 14.

13.

A retrospective analysis of post-transplant lymphoproliferative disorder following liver transplantation.

Fararjeh FA, Mahmood S, Tachtatzis P, Yallop D, Devereux S, Patten P, Agrawal K, Suddle A, O'Grady J, Heaton N, Marcus R, Kassam S.

Eur J Haematol. 2018 Jan;100(1):98-103. doi: 10.1111/ejh.12988. Epub 2017 Dec 4.

PMID:
29094407
14.

Outpatient management of steroid-induced hyperglycaemia and steroid-induced diabetes in people with lymphoproliferative disorders treated with intermittent high dose steroids.

Vidler J, Rogers C, Yallop D, Devereux S, Wellving E, Stewart O, Cox A, Hunt KF, Kassam S.

J Clin Transl Endocrinol. 2017 Jun 24;9:18-20. doi: 10.1016/j.jcte.2017.06.003. eCollection 2017 Sep.

15.

A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.

Pratt G, Yap C, Oldreive C, Slade D, Bishop R, Griffiths M, Dyer MJS, Fegan C, Oscier D, Pettitt A, Matutes E, Devereux S, Allsup D, Bloor A, Hillmen P, Follows G, Rule S, Moss P, Stankovic T.

Br J Haematol. 2018 Aug;182(3):429-433. doi: 10.1111/bjh.14793. Epub 2017 Jun 23. No abstract available.

PMID:
28643365
16.

Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study.

Dhanapal V, Gunasekara M, Lianwea C, Marcus R, De Lord C, Bowcock S, Devereux S, Patten P, Yallop D, Wrench D, Fields P, Kassam S.

Leuk Lymphoma. 2017 Sep;58(9):1-9. doi: 10.1080/10428194.2016.1276288. Epub 2017 Jan 16.

PMID:
28093003
17.

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome.

Eyre TA, Clifford R, Bloor A, Boyle L, Roberts C, Cabes M, Collins GP, Devereux S, Follows G, Fox CP, Gribben J, Hillmen P, Hatton CS, Littlewood TJ, McCarthy H, Murray J, Pettitt AR, Soilleux E, Stamatopoulos B, Love SB, Wotherspoon A, Schuh A.

Br J Haematol. 2016 Oct;175(1):43-54. doi: 10.1111/bjh.14177. Epub 2016 Jul 5.

PMID:
27378086
18.

Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration.

Pasikowska M, Walsby E, Apollonio B, Cuthill K, Phillips E, Coulter E, Longhi MS, Ma Y, Yallop D, Barber LD, Patten P, Fegan C, Ramsay AG, Pepper C, Devereux S, Buggins AG.

Blood. 2016 Jul 28;128(4):563-73. doi: 10.1182/blood-2016-01-683128. Epub 2016 Jun 1.

19.

ALK-positive large B-cell lymphoma with strong CD30 expression; a diagnostic pitfall and resistance to brentuximab and crizotinib.

Mehra V, Pomplum S, Ireland R, Yallop D, Devereux S, Marcus R, Shah C, Patten P, Kassam S.

Histopathology. 2016 Nov;69(5):880-882. doi: 10.1111/his.13002. Epub 2016 Jul 19. No abstract available.

PMID:
27238948
20.

Long-Lived Excited-State Dynamics of i-Motif Structures Probed by Time-Resolved Infrared Spectroscopy.

Keane PM, Baptista FR, Gurung SP, Devereux SJ, Sazanovich IV, Towrie M, Brazier JA, Cardin CJ, Kelly JM, Quinn SJ.

Chemphyschem. 2016 May 4;17(9):1281-7. doi: 10.1002/cphc.201501183. Epub 2016 Feb 17.

PMID:
26879336

Supplemental Content

Loading ...
Support Center